The level of PD-1 expression has been proved by recent studies to be positively correlated with the extent of HBV-specific T cell impairments. However, the degree of T cell exhaustion which affects the disease statuses of hepatitis B patients has so far been only evaluated in restricted and small groups of patients between those with established chronicity and subjects with acute HBV infection.

In a first-of-its-kind finding, researchers at The University of Texas M. D. Anderson Cancer Center have discovered that exposure to the hepatitis B virus (HBV) may increase the risk of pancreatic cancer.

Patients with IBD have high risk of infection by hepatitis viruses B or C because during the course of their disease, they need blood transfusions, and sometimes surgical and endoscopic procedures for diagnosis and treatment.

Mummies that have recently been unearthed in South Korea may provide clues on how to combat hepatitis B, according to Prof. Mark Spigelman of the Kuvin Center for the Study of Infectious and Tropical Diseases at the Hebrew University of Jerusalem.

Since the transmission of HIV and Hepatitis B virus (HBV) are so similar, individuals infected with one of these viruses are at a significantly increased risk for contracting the other.

Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine.

In the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD), researchers report their findings from the first-ever study examining the prognostic value of serum hepatitis B virus DNA levels for patients with liver cancer undergoing chemotherapy.